Abstract
The Cdc37 gene encodes a 50 kDa protein which targets intrinsically unstable oncoprotein kinases such as Cdk4, Raf-1, and src to the molecular chaperone Hsp90. This activity is thought to play an important role in the establishment of signaling pathways controlling cell proliferation. The budding yeast Cdc37 homolog is required for cell division and mammalian Cdc37 is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation. Here we report that human prostatic tumors, neoplasias and certain pre-malignant lesions display increased Cdc37 expression, suggesting an important and early role for Cdc37 in prostatic transformation. To test the consequences of increased Cdc37 levels, transgenic mice expressing Cdc37 in the prostate were generated. These mice displayed a wide range of growth-related abnormalities including prostatic epithelial cell hyperplasia and dysplasia. These data suggest that the expression of Cdc37 may promote inappropriate proliferation and may be an important early step in the development of human prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aaltomaa S, Eskelinen M and Lipponen P . 1999 Prostate 38: 175–182
Aktas H, Cai H and Cooper GM . 1997 Mol Cell Biol 17: 3850–3857
Bangma CH, Nasu Y, Ren C and Thompson TC . 1999 Semin Oncol 26: 422–427
Brugge JS . 1986 Curr Topics Microb Immunol 123: 1–22
Brugge J . 1981 Cell 25: 363–372
Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G and Kallioniemi OP . 1999 Cancer Res 59: 803–806
Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM and Sherr CJ . 1999 EMBO J 18: 1571–1583
Cheng M, Sexl V, Sherr CJ and Roussel MF . 1998 Proc Natl Acad Sci USA 95: 1091–1096
Coffey DS . 1992 Campbell's Urology, Vol 1, 6th ed Walsh PC, Retik AB, Stamey TA and Vaughan, Jr ED eds. WB Saunders Co Philadelphia pp221–266
Connell-Crowley L, Harper JW and Goodrich DW . 1997 Mol Biol Cell 8: 287–301
Cutforth T and Rubin GM . 1994 Cell 77: 1027–1036
Dai K, Kobayashi R and Beach D . 1996 J Biol Chem 271: 22030–22034
Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J and Livingston DM . 1993 Cell 73: 487–497
Gerber MR, Farrell A, Deshaies RJ, Herskowitz I and Morgan DO . 1995 Proc Natl Acad Sci USA 92: 4651–4655
Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN and Cochran BH . 1999 Mol Cell Biol 19: 1661–1672
Greenberg NM, DeMayo FJ, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM . 1995 Proc Natl Acad Sci USA 92: 3439–3443
Han EK, Lim JT, Arber N, Rubin MA, Xing WQ and Weinstein IB . 1998 Prostate 35: 95–101
Hutchison KA, Brott BK, De Leon JH, Perdew GH, Jove R and Pratt WB . 1992 J Biol Chem 267: 2902–2908
Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman Jr RP and Ross JS . 1997 Cancer 80: 753–763
Kato J, Matsuoka M, Polyak K, Massague J and Sherr CJ . 1994 Cell 79: 487–496
Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ . 1993 Genes Dev 7: 331–342
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E . 1997 Genes Dev 11: 847–862
Lamphere L, Fiore F, Xu X, Brizuela L, Keezer S, Sardet C, Draetta GF and Gyuris J . 1997 Oncogene 14: 1999–2004
Landis SH, Murray T, Bolden S, et al. 1999 CA Cancer J Clin 49: 8–31
Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ and Kato JY . 1994 Mol Cell Biol 14: 2066–2076
McConnell BB, Gregory FJ, Stott FJ, Hara E and Peters G . 1999 Mol Cell Biol 19: 1981–1989
Meyerson M and Harlow E . 1994 Mol Cell Biol 14: 2077–2086
Munoz MJ and Jimenez J . 1999 Mol Gen Genet 261: 242–250
Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA and Ewen ME . 1997 Nature 386: 177–181
Reynisdottir I, Polyak K, Iavarone A and Massague J . 1995 Genes Dev 9: 1831–1845
Reynisdottir I and Massague J . 1997 Genes Dev 11: 492–503
Sharma P and Schreiber-Agus N . 1999 Oncogene 18: 5349–5355
Sherr CJ and Roberts JM . 1999 Genes Dev 13: 1501–1512
Stancato LF, Chow Y-H, Hutchison KA, Perdew GH, Jove R and Pratt WB . 1993 J Biol Chem 268: 21711–21716
Stepanova L, Leng X, Parker S and Harper JW . 1996 Genes Dev 10: 1491–1502
Stepanova L, Finegold M, DeMayo F, Schmidt EV and Harper JW . 2000 Mol Cell Biol in press
Thompson TC, Timme TL, Bangma CH, Nasu Y, Hull GW, Hall SJ and Stapleton AMF . 1999 Comprehensive Textbook of Genitourinary Oncology Coffey DS, Scardino PT, Shipley WU and Vogelzang NJ eds. Williams & Wilkins Baltimore, Maryland
Tamboli P, Amin MB, Xu HJ and Linden MD . 1998 Mod Pathol 11: 247–252
Walsh PC . 1992 Campbell's Urology, Vol 1, 6th ed Walsh PC, Retik AB, Stamey TA and Vaughan Jr, ED eds. WB Saunders Co Philadelphia pp1007–1022
Whitelaw ML, Hutchison K and Perdew GH . 1991 J Biol Chem 266: 16436–16440
Xu Y, Singer MA and Lindquist S . 1999 Proc Natl Acad Sci USA 96: 109–114
Acknowledgements
We thank Norman Greenberg for access to microscope facilities. This work was supported by grants from the NIH (GM54137) and the Welch Foundation to JW Harper, and by the Baylor SPORE in Prostate Cancer (NCI P50-58204) to TC Thompson. L Stepanova is supported by a Pre-Doctoral training grant from the Department of Defense.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stepanova, L., Yang, G., DeMayo, F. et al. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19, 2186–2193 (2000). https://doi.org/10.1038/sj.onc.1203561
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203561
Keywords
This article is cited by
-
Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity
Acta Pharmacologica Sinica (2022)
-
Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
Journal of Hematology & Oncology (2018)
-
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15
Investigational New Drugs (2016)
-
Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins
Oncogene (2015)
-
The C-terminal domain of human Cdc37 studied by solution NMR
Journal of Biomolecular NMR (2015)